Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Early dynamics of a neutrophil interferon program drive immunotherapy resistance and limit durable anti-tumor immunity

Despite the remarkable success of immune checkpoint blockade (ICB), durable clinical benefit remains limited to a subset of patients, highlighting the need for predictive biomarkers and new therapeutic targets. Here, we investigated the early immune dynamics associated with anti-PD1 responsiveness using longitudinal single-cell transcriptomics, spatial transcriptomics, and neutrophil-specific…

We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.

Read the original at biorxiv.org →

More in Health & Medicine

More from Thursday 1 October →